Life Healthcare Group Holdings Limited has announced the fulfillment of all Conditions Precedent for the disposal of its interests in Life Molecular Imaging to Lantheus Holdings Inc., as defined in their Sale and Purchase Agreement. The transaction is expected to conclude on 21 July 2025. Life Healthcare plans, pending board approval, to return the net proceeds from the upfront payment to shareholders within the next 12 months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.